AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday. The agreement with Algen gives AstraZeneca ...

The agreement with Algen Biotechnologies gives AstraZeneca exclusive rights to develop and commercialise therapies from the ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

Treatment introduces an expansion of the scope of gene therapies that might lead to similar treatments for neurodegenerative ...

A gene-editing tool that can turn genes on and off like a light switch has been developed. Turning a gene on means activating the production of ...

EXTON, PA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is emerging within ...

Cayman Chemical, a global provider of life science research tools, and Akadeum Life Sciences, a leader in buoyancy-based cell ...

G lobal pharmaceutical giant AstraZeneca has penned a $555 million with Algen Biotechnologies, a San Francisco-based ...

The inaugural Genetic Agency Technology Conference (GATC) on November 11th, 2025 will convene technical thought leaders, gene therapy developers, patients, their families, and patient advocates across ...

In a development that could help protect one of the world's most beloved agricultural commodities, a research team at Penn ...

Researchers from the Department of Biomedical Engineering at UNIST and the Center for Genomic Integrity at the Institute for Basic Science (IBS) have announced an advance in cancer gene therapy. Their ...

Founded in 2020 by Chilean biochemist Bernardo Pollak, Meristem is using precise gene editing techniques to develop local ...